SangHoon Park - Korean Drug Chief Director
| 014570 Stock | KRW 4,470 10.00 0.22% |
Insider
SangHoon Park is Chief Director of Korean Drug Co
| Age | 57 |
| Phone | 82 2 529 6100 |
| Web | https://www.nicepharma.com |
Korean Drug Management Efficiency
The company has return on total asset (ROA) of 0.0702 % which means that it generated a profit of $0.0702 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 15.3031 %, meaning that it generated $15.3031 on every $100 dollars invested by stockholders. Korean Drug's management efficiency ratios could be used to measure how well Korean Drug manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | INSIDER Age | ||
| MunHee Park | Kolon Life Science | N/A | |
| SangWoo Lee | Kolon Life Science | 59 | |
| SangJun Lee | Kolon Life Science | 62 | |
| TaeHwan Kim | Kolon Life Science | 73 | |
| KyungII Kim | Aminologics CoLtd | 65 | |
| YoonWoo Lee | Daihan Pharmaceutical CoLtd | 79 | |
| WooSok Lee | Kolon Life Science | 66 | |
| SangHu Park | Kolon Life Science | 61 | |
| MyungKwan Suh | Kolon Life Science | 61 | |
| HunYeol Yun | Aminologics CoLtd | 61 | |
| WonSup Kim | Aminologics CoLtd | 64 | |
| JaeGwan Lee | Aminologics CoLtd | 64 | |
Management Performance
| Return On Equity | 15.3 | |||
| Return On Asset | 0.0702 |
Korean Drug Leadership Team
Elected by the shareholders, the Korean Drug's board of directors comprises two types of representatives: Korean Drug inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Korean. The board's role is to monitor Korean Drug's management team and ensure that shareholders' interests are well served. Korean Drug's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Korean Drug's outside directors are responsible for providing unbiased perspectives on the board's policies.
| SangHoon Park, Chief Director | ||
| KyungDeuk Lee, Managing Director | ||
| SeungGwon Baek, Managing Director | ||
| KiPyung Lee, Managing Director | ||
| Hai Park, Chief Chairperson | ||
| HeeCheon Tak, Managing Director |
Korean Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Korean Drug a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 15.3 | |||
| Return On Asset | 0.0702 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 94.01 B | |||
| Shares Outstanding | 11 M | |||
| Shares Owned By Insiders | 50.19 % | |||
| Shares Owned By Institutions | 0.28 % | |||
| Price To Earning | 55.67 X | |||
| Price To Sales | 1.11 X |
Pair Trading with Korean Drug
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Korean Drug position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Korean Drug will appreciate offsetting losses from the drop in the long position's value.Moving together with Korean Stock
| 0.86 | 102940 | Kolon Life Science | PairCorr |
| 0.84 | 074430 | Aminologics CoLtd | PairCorr |
| 0.66 | 023910 | Daihan Pharmaceutical | PairCorr |
Moving against Korean Stock
The ability to find closely correlated positions to Korean Drug could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Korean Drug when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Korean Drug - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Korean Drug Co to buy it.
The correlation of Korean Drug is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Korean Drug moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Korean Drug moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Korean Drug can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Korean Stock
Korean Drug financial ratios help investors to determine whether Korean Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Korean with respect to the benefits of owning Korean Drug security.